Cargando…

The humoral response of mRNA COVID-19 vaccine in hematological diseases: The HEMVACO study

OBJECTIVES: The HEMVACO study evaluated the humoral response after mRNA anti-SARS-CoV-2 vaccination in an hematological cohort. METHODS: HEMVACO was a prospective, multicentric study registered in ClinicalTrials.gov, number NCT04852796. Patients received two or three doses of BNT162b2 vaccine or mRN...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gueguen, M., Khatchatourian, L., Lohéac, C., Dorval, I., Mercier, M., Le Calloch, R., Mahé, K., Rizcallah, M.J., Hutin, P., Fangous, M.S., Saidani, N., Le Clech, L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Masson SAS. 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164434/ https://www.ncbi.nlm.nih.gov/pubmed/35667558 http://dx.doi.org/10.1016/j.idnow.2022.05.008

Ejemplares similares

Membranous nephropathy following anti–COVID-19 mRNA vaccination
por: Gueguen, Lorraine, et al.
Publicado: (2021)

« Et si nous vaccinions directement dans les services? » Évaluation de la tolérance du vaccin AztraZeneca chez les soignants sur la première semaine de campagne vaccinale
por: Cloarec, E., et al.
Publicado: (2021)

Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies
por: Jiménez, Moraima, et al.
Publicado: (2022)

Réponse immunitaire humorale après VAccination contre la COVID19 au sein d’une cohorte française de patients hémoDIALysés (COVADIAL)
por: Loheac, C., et al.
Publicado: (2021)

Role of CAP350 in Centriolar Tubule Stability and Centriole Assembly
por: Le Clech, Mikael
Publicado: (2008)

CD8 T cells compensate for impaired humoral immunity in COVID-19 patients with hematologic cancer
por: Bange, Erin M., et al.
Publicado: (2021)

Evaluation of the Humoral and Cellular Immune Response Post COVID-19 Infection in Kidney Transplant Recipients
por: Bensaid, Kahina, et al.
Publicado: (2023)

Hemorrhagic Cystitis due to BK Reactivation in a Young Female Treated for Hodgkin-Disease
por: Le Calloch, R., et al.
Publicado: (2011)

Correlation between BNT162b2 mRNA Covid-19 vaccine-associated hypermetabolic lymphadenopathy and humoral immunity in patients with hematologic malignancy
por: Cohen, Dan, et al.
Publicado: (2021)

Humoral Response to the Third-Dose COVID-19 Vaccination in Patients with Hematological Malignancy
por: Ikeda, Daisuke, et al.
Publicado: (2022)

Le défi : roman
por: Le Clec'h, Guy, 1917-
Publicado: (1954)

A third injection of the BNT162b2 mRNA COVID-19 vaccine in kidney transplant recipients improves the humoral immune response
por: Masset, Christophe, et al.
Publicado: (2021)

150 ejercicios de ajedrez : fácil, medio, difícil : mejore su nivel /
por: Lohéac-Ammoun, Frank
Publicado: (1997)

Compruebe su nivel de ajedrez : refuerce su ataque y su defensa, desarrolle su razonamiento, calcule su nivel
por: Lohéac-Ammoun, Frank

Humoral response to mRNA vaccines against SARS-CoV-2 in patients with humoral immunodeficiency disease
por: Bitzenhofer, Michaela, et al.
Publicado: (2022)

Study of humoral and cellular immunity in vaccinated with mRNA‐1273
por: Gutiérrez‐Bautista, Juan Francisco, et al.
Publicado: (2022)

Humoral immune responses during SARS-CoV-2 mRNA vaccine administration in seropositive and seronegative individuals
por: Fraley, Elizabeth, et al.
Publicado: (2021)

Evaluating Complement-Mediated Humoral Immunity to P. falciparum Blood Stages
por: Boyle, MJ, et al.
Publicado: (2016)

B Cell Aplasia Is the Most Powerful Predictive Marker for Poor Humoral Response after BNT162b2 mRNA SARS-CoV-2 Vaccination in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation
por: Jullien, Maxime, et al.
Publicado: (2022)

SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies
por: Haggenburg, Sabine, et al.
Publicado: (2022)

Humoral responses to SARS-CoV-2 mRNA vaccines: Role of past infection
por: Gray, Ashley N., et al.
Publicado: (2021)

Profound B-Cell Lymphopenia Is a Major Factor Predicting Poor Humoral Response after BNT162b2 mRNA Sars-Cov-2 Vaccines in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation
por: Jullien, Maxime, et al.
Publicado: (2021)

Humoral response to 2-dose BNT162b2 mRNA vaccine for Covid-19 in liver transplant recipients
por: Guarino, M., et al.
Publicado: (2022)

Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial
por: El Sahly, Hana M, et al.
Publicado: (2022)

Blunted humoral response after mRNA vaccine in patients with haematological malignancies
por: Kamboj, Mini
Publicado: (2021)

Predictors of Humoral Response to COVID-19 Vaccination in Heart Transplant Recipients
por: Memenga, F., et al.
Publicado: (2022)

SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity
por: Jaycox, Jillian R., et al.
Publicado: (2023)

An unusual giant serpiginous lesion of secondary syphilis
por: Grimaux, Xavier, et al.
Publicado: (2018)

Development of humoral immunity
por: Kanellopoulos, Jean M., et al.
Publicado: (2019)

Beyond the joints in rheumatoid arthritis: Effects of adalimumab on hematologic and lipid indices
por: Sakthiswary, R., et al.
Publicado: (2012)

OC.15.2 HUMORAL RESPONSE TO 2-DOSE BNT162B2 MRNA VACCINE FOR COVID-19 IN LIVER TRANSPLANT RECIPIENTS
por: Guarino, M., et al.
Publicado: (2022)

Humoral immune response to COVID-19 mRNA vaccination in relation to selenium status
por: Demircan, Kamil, et al.
Publicado: (2022)

Humoral response to mRNA‐based COVID‐19 vaccine in patients with myeloid malignancies
por: Mori, Akio, et al.
Publicado: (2022)

Humoral response to mRNA‐based COVID‐19 vaccine in patients with immune thrombocytopenia
por: Mori, Akio, et al.
Publicado: (2022)

Longitudinal SARS-CoV-2 mRNA Vaccine-Induced Humoral Immune Responses in Patients with Cancer
por: Figueiredo, Jane C., et al.
Publicado: (2021)

Evolution of Humoral and Cellular Immunity Post–Breakthrough Coronavirus Disease 2019 in Vaccinated Patients With Hematologic Malignancy Receiving Tixagevimab-Cilgavimab
por: Hall, Victoria G, et al.
Publicado: (2023)

Update on the role of copanlisib in hematologic malignancies
por: Le, Thuy, et al.
Publicado: (2021)

Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis
por: Strengert, Monika, et al.
Publicado: (2021)

Anti-spike T-cell and Antibody Responses to SARS-CoV-2 mRNA Vaccines in Patients with Hematologic Malignancies
por: Greenberger, Lee M., et al.
Publicado: (2022)

Cellular and humoral immune response to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia
por: Lyski, Zoe L., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qkdnp7k2qr0fc7cp8dq1c7040t